Health, Science

Researchers say the new immunotherapy drugs can target two types of evasive cancer-driving proteins

Scientific research has shown that new immunotherapy drugs can target two types of evasive cancer-driving proteins.

By Anastasia Andric

March 5, 2021
at 8:00 AM

Scientific research has revealed that new immunotherapy drugs can target two evasive cancer-driving proteins. Through research in mice, it has been found that designer antibodies can stop the growth of tumours by targeting two proteins that are cancer’s most infamous offenders, the RAS and p53.

Researchers have known these proteins to mutate in many tumours and have defied most other drug development efforts. Researchers hope the new findings will hold up in clinical trials as the drugs could allow for the possibility of helping the immune system fight off hard-to-treat cancers such as ovarian and pancreatic.

ORIGINAL SOURCE

Anastasia Andric

Anastasia is a curious and enthusiastic storyteller, with a degree in Journalism from Ryerson University. She has a love for the news and is passionate about reporting on issues that matter. She is dedicated to informing the public with accurate, timely, and relevant news. She is not afraid to dig deep and ask the tough questions to get to the real story.